AACR 2026 现场信号· @ · X·· 2026-04-22评分60
正文 · 机器翻译
翻看我昨天收集的 #aacr26 海报。Prelude Tx 有一款处于早期开发阶段的 KAT6A 降解剂(PRT13722),旨在与抑制剂竞争:https://t.co/23zBtCX8Hs
热度 16 · 15 赞 · 0 回复 · 1 转发
会议摘要
5793按 代号 PRT13722 对上
First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profileMonisha Sivakumar, Sarah Pawley, Corey Basch, Jimin Park, Justin Kurian, Anthony Reichelderfer, Yue Zou, Kirsten Gallagher, Miles Cowart, Joy Cote, Alexander Grego, Jessica Burtell, Amy Crossan, Michael Hulse, Anjana Agarwal, Arpita Mondal, Chun Chen, Vijay Devannah, Sina Rezazadeh, Quincy Lewis, Patrick Wen, Ken Ray, Raul Leal, Daniel Porreca, Ganfeng Cao, Neha Bhagwat, Shanthi Ganesan, Stefan Ruepp, Min Wang, Joseph Rager, Koichi Ito, Sandy Geeganage, Andrew Combs, Peggy Scherle, Andrew Buesking, Jack Carter
读摘要原文 →来源:AACR 2026 现场信号 · x.com
